# TAC T-cells for the Treatment of HER2-positive Solid Tumors

> **NCT04727151** · PHASE1,PHASE2 · TERMINATED · sponsor: **Triumvira Immunologics, Inc.** · enrollment: 28 (actual)

## Conditions studied

- HER2 Positive Gastric Cancer
- Metastatic HER2 Positive Gastroesophageal Junction Cancer

## Interventions

- **BIOLOGICAL:** TAC01-HER2
- **BIOLOGICAL:** TAC01-HER2 plus pembrolizumab

## Key facts

- **NCT ID:** NCT04727151
- **Lead sponsor:** Triumvira Immunologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-19
- **Primary completion:** 2023-12-17
- **Final completion:** 2024-03-25
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor for commercial reasons
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04727151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04727151, "TAC T-cells for the Treatment of HER2-positive Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04727151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*